expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of the Company’s
this standard, the method of revenue recognition of the Company shall change. Non-performing loans purchased from financial institutions, which are under IFRS9 standards, are considered to be purchased
projects under implementation. More recently, Returns on Equity and on Capital Employed have surpassed the double-digit level. Specifically, for 2Q17, IVL achieved core ROE of 18.2% and a core ROCE of 12.6
million THB or 13.09% i.e. from 18,557.92 to 20,986.90 million THB. It is because the projects under development and inventory increase 1,515.20 million THB or 10% i.e. from 15,155.85 to 16,671.05 million
result of repayment of long-term loans from financial institutions, and increase in liability under hire purchase agreement amount of Baht 3.41 million. 3. Shareholder equity as at June 30, 2017 amount of
from trade and other payables of 159.76 million baht, other current liabilities of 6.18 million baht, and liabilities under financial lease of 0.63 million baht, decrease of short term loan from
product group came from the increased sales volumes; while unit sales prices of burnt products remained under considerable pressure compared with the same period last year. On the downside, there was a
to increasing of short-term liabilities under financial lease according to financial lease – medical equipment lease. Shareholders’ Equity As at June 30, 2017, the Company has shareholders' equity at
due to an expansion of the restaurants and bakery shops under the brand “S&P”. However, the growth of the domestic retail channels Earnings before Interest, Tax, Depreciation and Amortization (EBITDA